<DOC>
	<DOC>NCT00719823</DOC>
	<brief_summary>The objective of this study is to provide Maraviroc on a compassionate use basis to antiretroviral treatment experienced patients infected with CCR5-tropic HIV-1 with urgent unmet medical needs and who, in the opinion of the physician, require Maraviroc to form a viable regimen.</brief_summary>
	<brief_title>Maraviroc Compassionate Use</brief_title>
	<detailed_description>This study was cancelled prior to enrollment.</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Patients at least 16 years old with prior extensive treatment experience with limited further options in need of maraviroc to constitute an effective HIV1 treatment regimen. Have only CCR5tropic HIV1 virus CD4+ cell count &lt; 200 cells/mm3 CXCR4 or dual/mixedtropic HIV1 virus Patients who in the opinion of investigator are unlikely to derive benefit from maraviroc as a result of severity of illness Patients who are pregnant or breast feeding an infant or planning to become pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Maraviroc Compassionate Use</keyword>
</DOC>